$GIB

CGI Announces Acquisition Of Callibrity

CGI (GIB) acquired Callibrity, a consulting firm with 120 consultants, strengthening its Cincinnati market presence. The deal closed September 8, 2026. CGI shares rose 0.07% to $70.70 in pre-market trading.

Original reporting
Published Sep 9, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$GIB
Bullish
high confidence
Mentioned
$GIB
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GIBBullishMed
01

Why it matters

The acquisition is expected to broaden CGI's service offerings and deepen its market penetration in the Cincinnati region.

02

Market read

New M&A news for CGI provides a modest catalyst for the stock with potential medium‑term upside.

03

What to watch

Potential hidden liabilities of Callibrity and the cost of integration are not disclosed.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

CGI Inc. (GIB) is a global IT and business consulting services firm. The acquisition adds a boutique consulting team.

Company-level read

Ticker impact

$GIBBullishHigh confidence
Context

CGI announced it closed the acquisition of consulting firm Callibrity, adding 120 consultants and boosting its Cincinnati presence.

Expected impact

Modest upside as integration benefits are realized, but limited immediate move.

Evidence & confidence

Acquisitions of this nature typically enhance market positioning; no disclosed price suggests limited short‑term shock.

Market effects

Strengthens CGI's competitive stance in the consulting sector, especially for financial services and insurance clients.

May boost investor sentiment toward US tech services firms with Midwest expansion.

Limited global impact; primarily a US‑focused strategic move.

Counterpoint

Integration risks and modest deal size could limit upside, suggesting a wait‑and‑see approach.

Key entities

  • CGI Inc.

    Acquiring firm, ticker GIB.

  • Callibrity

    Target consulting firm adding 120 consultants.

Related articles

$GIBMedAI 9/10

CGI announces private offering of C$500 million, in aggregate, of 3.25 year and 4.75 year senior unsecured notes

CGI (TSX: GIB.A, NYSE: GIB) announced a C$500 million private offering of senior unsecured notes, split into C$250 million of 3.25-year notes at 4.195% and C$250 million of 4.75-year notes at 4.484%. Proceeds will repay debt and support general corporate purposes. The offering is expected to close on September 14, 2026, subject to conditions.

$GIBHigh

CGI INC (GIB): Financial results for Q3 2026

CGI INC (GIB) furnished an SEC Form 6-K — earnings release. GLOBAL PRESS RELEASE Stock Market Symbols GIB.A (TSX) GIB (NYSE) cgi.com/newsroom CGI reports third quarter Fiscal 2026 results Revenue up 2.5% and diluted EPS accretion of 22.5% Q3-F2026 performance highlights • Revenue of $4.19 billion, up 2.5% year-over-year or 1.3% year-over-

$GIBMed

CGI reports third quarter Fiscal 2026 results

CGI reported Q3 fiscal 2026 results. Revenue rose 2.5% to $4.19 billion (1.3% in constant currency). Diluted EPS increased 22.5% to $2.23, with net earnings up 13.8% to $465.2 million. Bookings were $4.20 billion and backlog $31.79 billion. The company declared a $0.17 quarterly dividend and reported $604.5 million operating cash flow.

$GIBMedAI 9/10

CGI To Take Over Telia Finland Cloud Unit, Add 250 Staff In Strategic Deal

CGI Inc. said it agreed to acquire Telia’s cloud and IT end-user services in Finland and form a strategic partnership with Telia. About 250 Telia employees will transfer to CGI, and the deal excludes Telia’s Helsinki Datacenter; terms were not disclosed and are subject to regulatory approval. CGI said it will expand Nordics data center capacity and offer high-security, hybrid and public cloud services.

$NVOHighAI 9/10

Orbis Medicines Partners With Novo In Up To $1.4 Billion Drug Discovery Deal

Orbis Medicines, a private company, partnered with Novo Nordisk (NVO) to develop oral therapies for cardiometabolic diseases. The deal could be worth up to $1.4B, including milestone payments and royalties. Novo Nordisk will also invest in Orbis, though the amount was not disclosed. NVO's stock closed at $43.19, up 3.55%, and was at $43.23 in overnight trading.